Education on Demand
Welcome to our Education on Demand group. Discuss the latest presentations, subscribe to be alerted of... View more
Organizers:
- Organized by
-
-
2024 Conference – Assessing and Treating the Emergence of Micro-Clotting
-
2024 Conference – Assessing and Treating the Emergence of Micro-Clotting
Micro-clotting has emerged as a critical concern, especially following COVID-19 and related vaccinations. In this lecture, Dr. Jordan Vaughn, CEO and Owner of MedHelp Clinics, addresses this challenge head-on. Drawing from his family’s medical legacy, Dr. Vaughn has made significant strides in identifying and treating micro-clotting, which is distinct from traditional clotting disorders. He presents innovative treatments tailored for spike-protein-related conditions. Dr. Vaughn’s insights emphasize the importance of recognizing and managing microvascular damage, offering hope through advanced medical strategies.
covid19criticalcare.com
2024 Conference - Assessing and Treating the Emergence of Micro-Clotting
Assessing and Treating the Emergence of Micro-Clotting Lecture abstract: Micro-clotting has emerged as a critical concern, especially following COVID-19 and related vaccinations. In this lecture, Dr. Jordan Vaughn, CEO and Owner of MedHelp Clinics, addresses this challenge head-on. Drawing from … Continue reading
-
1 Reply
-
This is Michael Ferres , a G.P. in Australia, a newcomer to this information about treating the consequences of spike protein exposure. I can see the value of treating microclots. When patients have had angioplasties or stents for coronary disease they are usually treated postoperatively for some months with aspirin and a platelet agent, but not anticoagulation. Is there any risk with triple therapy of aspirin and clopidogrel and DOAC, especially if nattokinase is also used?
Log in to reply.